Leading global investment firm finalizes its strategic investment in the rapidly growing dossier development house
Adalvo is pleased to announce the completion of EQT’s acquisition of a majority stake in the company. The strategic partnership marks a significant milestone in Adalvo’s journey and enables a new phase of growth.
Since its founding in 2018, Adalvo has established itself as a key player in global B2B pharmaceuticals, becoming one of Europe's fastest-growing pharmaceutical companies. Headquartered in Malta, with around 300 employees and offices in 15 countries across Europe and India, the company has developed an impressive portfolio of over 130 differentiated medicines. Today, Adalvo partners with more than 170 generic companies across 140+ markets, playing an important role in increasing access to affordable healthcare.
EQT’s investment will help Adalvo expand its portfolio, strengthen its supply chain, and deliver more business development opportunities through greater flexibility, reach, and speed to market.
Anil Okay, Adalvo’s CEO, commented: “We’re delighted to close the transaction and welcome EQT as our new partners. Their long-term vision, cultural alignment, and proven track record in healthcare make them an ideal match for our ambition. I’m excited to lead Adalvo in the next phase of our journey as CEO and co-investor with EQT. Together, we’ll make Adalvo the world’s leading B2B pharmaceutical company.”
With the transaction completed, Adalvo is poised to accelerate its growth with targeted investments in R&D, supply chain optimization, and operational excellence. The partnership with EQT provides strategic support and resources to expand Adalvo’s differentiated product portfolio, enhance its global reach, and deliver even greater value to partners and patients worldwide.